BRD4 and triple-negative breast carcinoma: It also showed potent activities to degrade BRD4 and inhibited cell proliferation in patient-derived secondary acute myeloid leukemia [42], triple negative breast cancer, ovarian cancer [39], and multiple myeloma cells [46].